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Abstract: The degradation of HIV-derived proteins into epitopes displayed by MHC-I or 
MHC-II are the first events leading to the priming of HIV-specific immune responses and to 
the recognition of infected cells. Despite a wealth of information about peptidases involved 
in protein degradation, our knowledge of epitope presentation during HIV infection remains 
limited. Here we review current data on HIV protein degradation linking epitope production 
and immunodominance, viral evolution and impaired epitope presentation. We propose that 
an in-depth understanding of HIV antigen processing and presentation in relevant primary 
cells  could  be  exploited  to  identify  signatures  leading  to  efficient  or  inefficient  epitope 
presentation in HIV proteomes, and to improve the design of immunogens eliciting immune 
responses efficiently recognizing all infected cells. 
Keywords:  HIV;  antigen  processing;  protein  degradation;  proteasome;  aminopeptidase; 
peptidase; immunogen; vaccine vector; dendritic cells; T cells; viral evolution 
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1. Antigen Processing Pathways 
Protein  degradation  by  the  antigen  processing  machinery  is  a  continuous  process  regulating  all 
cellular functions by defining the lifespan of all proteins, discarding misfolded proteins, recycling amino 
acids to make new proteins, and initiating immune monitoring [1]. 
Proteins and misfolded or incomplete translation products such as defective ribosomal products [2] 
are degraded by proteasomes, the most ubiquitous cellular proteases. Proteasomes are made of 4 rings,  
2 outer rings of 7 distinct alpha subunits and 2 inner rings of 7 distinct beta subunits, including 3 catalytic 
subunits cleaving after hydrophobic, acidic or basic residues respectively, allowing for the cleavage of all  
substrates [3,4]. The 20S core proteasomes can be fitted with regulatory lids leading to the assembly of 
26S proteasomes. The 19S lid interacts with E3 ubiquitin ligases and polyubiquitinated substrates and 
contributes to unfolding substrates before degradation and opening of the proteasome chamber. Whereas 
26S  proteasomes  degrade  mostly  polyubiquitinated  substrates,  20S  proteasomes  and  proteasomes 
capped with regulatory PA28/11S lids are able to degrade non-polyubiquitinated substrates. Besides 
constitutive proteasomes expressed in all cell types, immunoproteasomes are present in lymphoid tissues 
and  can  be  induced  in  other  cell  types  upon  infection  or  cytokine  exposure  [5].  Interferon  gamma 
induces the expression of catalytic immunosubunits and PA28 lids leading to the assembly of 20S and 
26S immunoproteasomes [6]. All proteasomes degrade proteins into fragments ranging from a few 
residues up to 32 aa long, including epitopes, peptides containing epitopes (epitope precursors) and also 
amino acids to be recycled for protein synthesis [7]. Although peptides generated by various types of 
proteasomes overlap, they may also create unique peptides [7,8]. Immunoproteasomes tend to produce 
longer peptides ending with C-terminal hydrophobic residues, the most frequent C-terminal anchor for 
most MHC-I isotypes, and may favor the production of epitopes [9]. The presence of both proteasomes 
and immunoproteasomes in the same cell is associated with a greater variety of peptides available for 
presentation [10]. Degradation products from the proteasome can be further degraded by proteasomes 
as well as other cytosolic peptidases including endopeptidases TPPII [11,12], thimet oligopeptidases 
(TOP) [13–15], leucine aminopeptidase (LAP) [11,12], puromycin sensitive aminopeptidase (PSA) 
[16], bleomycin sensitive hydrolase (BH) [17], insulin degrading enzyme [18] or nardilysin [19]. Each 
peptidase  has  specificities  in  terms  of  substrate  length  and  residues  but  they  are  not  always  well 
defined. The contribution of post-proteasomal peptidases is variable according to epitopes [18,19], 
sometimes  controversial  [20–22],  and  the  order  in  which  they  cleave  substrates  is  rarely  defined 
[23,24].  Cytosolic  peptidases  cannot  unfold  proteins  and  therefore  degrade  post-proteasomal 
degradation products. Post-proteasomal peptidases such as TOP can produce epitopes from longer 
precursors or destroy peptides, thus contributing to defining sequences and the amount of peptides 
available for presentation to T cells [15,25]. Cytosolic peptides of mostly 8–16 aa long with adequate 
anchor residues for the transporter associated to antigen processing (TAP) [26] are translocated into 
the  endoplasmic  reticulum  (ER)  where  peptides  can  be  trimmed  by  ER-resident  aminopeptidases 
ERAP1 [21,27–29] and ERAP2 [30] before loading onto MHC-I. Exogenous antigens such as proteins, 
dead cells, antibodies-coated viruses can be endocytosed or phagocytosed and degraded by various 
cathepsins [31,32], proteases and IRAP [33] in endosomes and lysosomes. Some degradation peptides 
can be transferred back in the cytosol or ER for further trimming and cross-presentation by MHC-I.  
In cells expressing MHC-II a specific lysosomal compartment called MIIC enables loading of peptides Viruses 2014, 6  3273 
 
 
onto MHC-II molecules after removal of the invariant chain [34]. Although MHC-II epitope processing 
is mostly accomplished by endolysosomal proteases, proteasomes may be involved in the production of 
MHC-II epitopes of endogenous origin. The distinction between endogenous and exogenous processing 
pathways is becoming more tenuous as many combinations of peptidases and compartments may be 
involved  in  the  presentation  or  cross-presentation  of  peptides  [35].  Additionally,  the  variable 
intracellular stability of peptides prior to loading onto MHC-I alters the amount of peptides available 
for MHC-I presentation [36,37]. Altogether the location, trafficking path and the presence or absence of 
cleavable motifs by various peptidases will shape the degradation patterns of proteins [38]. 
2. Degradation of HIV Proteins into Epitopes 
Despite rather extensive knowledge of protein degradation pathways and high-throughput methods 
to sequence HIV in large cohorts of patients, our capacity to rapidly identify or predict T cell epitopes 
in  pathogen-derived  proteins  after  infection  or  vaccination  is  still  cumbersome,  mostly  relying  on 
screening of T cell responses by Elispot using PBMCs from infected persons. The identification of 
potential anchor residues for various MHC-I isotypes in HIV sequences shows that there are more 
putative  epitopes  than  actual  immune  responses,  suggesting  limitations  in  either  production  of 
peptides, their presentation by MHC or available TCR repertoire. We still do not know which HIV 
peptides are actually processed and presented by HIV-infected cells. These studies are still technically 
difficult due to the high number of infected cells required for peptide extraction. The first evidence of 
presentation  of  HIV  peptides  by  HIV-infected  cell  lines  came  through  acid  elution  and  HPLC 
purification of peptide fractions reactive against HIV-specific CD8 T cells [39]. A second study using 
HIV-infected cells secreting soluble HLA (to enhance the amount of HLA collected and sensitivity of 
the assay) identified by mass spectrometry numerous self-derived peptides eluted off soluble HLA 
molecules, and showed changes in the amount or identity of self-derived peptides. It did not lead to the 
identification of HIV peptides, possibly due to HIV peptide presentation being below the threshold of 
detection  by  mass  spectrometers  [40].  Another  study  identified  HIV-derived  MHC-II  peptides 
presented by DC endocytosing p24 coupled to anti-DEC205 antibody [41]. Increased sensitivity of 
new mass spectrometers and various improvements in assays and mass spectrometry data analysis 
software  will  probably  lead  to  the  identification  of  a  landscape  of  HIV  and  self-derived  epitopes 
presented by HIV-infected cells in a near future. However, MHC-bound peptides from HIV-infected 
cells will always be limited by the combination of HLA of the donor and the technological limit of 
detection of peptides. It is necessary to better understand how HIV proteins are degraded into peptides 
in cells to evaluate the capacity of proteins (or immunogens) to generate peptides compatible with 
loading onto MHC-I or MHC-II, and the impact of cell type or infection on HIV epitope presentation. 
In addition to epitopes encoded by the conventional reading frames of HIV genes several groups 
identified cryptic epitopes derived from the degradation of HIV translation products derived from 
alternate reading frames of HIV shifted by 1, 2 or 3 bases during translation [42]. Cryptic epitopes 
elicited  CTL  responses  and  immune  pressure  leading  to  HLA-restricted  intraepitopic  mutations 
[43,44], including some impairing processing [45]. Whether these immune responses contribute to 
reducing viral load in natural infection or should be included in vaccine immunogens is still unknown. Viruses 2014, 6  3274 
 
 
This new category of HIV-derived epitopes highlights our limited knowledge of the source of HIV 
epitopes and peptides presented by HIV-infected cells. 
To study epitope production and presentation several experimental systems have been developed. 
The use of HIV-infected cells as targets for assays measuring HIV-specific T cell functions (killing, 
proliferation, cytokine production) measures both endogenous processing and presentation of epitopes 
and variability of MHC-peptide-TCR, and is limited by the availability of HIV-specific T cell clones. 
In vitro degradation of HIV proteins by purified proteasomes [46–48], ERAP1 [49,50] or by specific 
purified cathepsins [51] enables detailed studies of degradation patterns and cleavage preferences by 
specific peptidases. In vitro proteasomal degradation of Nef showed production of numerous peptides 
in epitope-rich areas of Nef enriched in hydrophobic residues [46]. Degradation of HIV p24 or p17 by 
proteasomes and ERAP1 also led to the efficient production of peptides containing immunodominant 
epitopes  [49,50].  Degradation  of  HIV  Env  by  purified  cathepsins  showed  efficient  production  of 
epitopes  (compared  to  proteasomal  degradation)  that  may  contribute  to  elicitation  of  CD4  T  cell 
responses [51]. Single peptidase degradation facilitates the assessment of mutations on the production 
of  epitope  precursors  or  epitopes  at  a  specific  step  of  antigen  processing  [50,52].  However  since 
protein degradation is a continuum involving multiple proteases (or several variants of proteasome 
species such as  20S/26S in  the  same  cell), this  approach may  not  permit the investigation of the 
complete processing of an epitope. Additionally, peptidases are often purified from cell lines that may 
not always be the most relevant to HIV infection. The use of intracellular compartments for protein 
degradation (cytosol, endosomes, lysosomes) allows us to account for all peptidases present in a given 
compartment  and  a  given  cell  type or  infection (although we cannot completely  rule  out that the 
preparation of subcellular fractions by damaging the normal structure of compartments may have some 
impact on protein degradation kinetics or patterns). The degradation of HIV proteins or long peptides 
in cytosolic extracts of primary cells showed that the kinetics of epitopes is variable even among 
overlapping epitopes [53,54], and that the efficiency of production of epitopes (timing and amount) is 
defined by motifs located within and outside epitopes [47,49,53,55,56], and the intracellular stability 
of peptides before loading onto MHC [36]. 
HIV virions enter cells by fusion at the plasma membrane and by endocytosis or antibody-mediated 
phagocytosis for immune complexes. Vaccines such as viral vectors or nanoparticles decorated with 
peptides  or  proteins  enter  dendritic  cells  by  endocytosis.  Degradation  of  HIV  Envelope  after 
deglycolysation  showed  poor  proteasomal  degradation  and  efficient  degradation  by  cathepsins,  in 
accordance  with  intrinsic  differences  in  antigen  degradation  according  to  peptidases’  substrate 
preferences [51]. Side-by-side degradations of HIV proteins in cytosolic and endolysosomal extracts 
from primary cells showed that some MHC-I epitopes are similarly processed in the two pathways 
while others are better processed in one of them [57]. These results suggest that the mode of entry of 
HIV  virions  or  immunogens,  in  addition  to  the  subset  of  target  cells,  will  affect  production  and 
presentation of HIV epitopes as shown in non-HIV models [58,59]. 
A corollary to studies on efficiency of epitope production is to better understand mechanisms leading 
to impaired epitope presentation in the context of viral evolution. HLA-restricted mutations occur 
frequently  in  HIV-infected  individuals  during  acute  and  chronic  infection  [60–65].  Some  of  these 
mutations are induced by immune pressure to avoid epitope presentation or correspond to mutations 
restoring viral fitness [66–73]. Many HLA-restricted mutations within epitopes impair binding to MHC-I Viruses 2014, 6  3275 
 
 
or to the TCR of CD8 T cells [67,74,75]. Mutations outside epitopes may affect the trimming of 
extended peptides into epitopes or change the degradation of long peptides by proteasomes [45,76–80]. 
Two recent studies identified motifs corresponding to antigen processing mutations at the population 
level by defining residues that can or cannot be cleaved by families of peptidases or group of peptidases 
in a subcellular compartment. One study identified residues that can be variably cleaved or not cleaved 
by aminopeptidases (some of which had been previously identified [81,82]), and demonstrated that the 
presence of poorly or non cleavable motifs introduced near an HIV epitope reduced or abolished 
epitope production in vitro and presentation to T cells [55]. In a population of over 1000 HIV-infected 
persons, N-flanking mutations evolved mostly toward poorly cleavable residues, showing that antigen 
processing mutations are frequent and can be predicted [55]. In another study that defined motifs linked 
to  intracellular  peptide  stability  or  instability,  a  number  of  intraepitopic  HLA-restricted  mutations 
identified in a large population of HIV-infected persons (21 out of 25 mutants tested so far) led to 
decreased cytosolic stability and decreased the amount of peptide presented to CTL [36]. Thus, HIV has 
developed many ways to block epitope presentation through peptide destruction or through impaired 
trimming of long peptides into peptides better suited for MHC-I binding [83], leading to suboptimal 
presentation of peptides to CD8 T cells and impaired clearance of infected cells. 
The accumulation of data on protein degradation by purified proteasomes led to the development of 
prediction  tools  such  as  NetChOP  or  PaProC  to  define  potential  cleavage  sites  in  proteins  of  
interest [84–87]. Although they do not account for the impact of infection or specifics of proteasomes 
in relevant primary cells they are valuable tools to identify potential proteasomal cleavage sites in an 
antigen.  Improvements  to  these  predictors  for  epitope  processing  came  by  incorporating  binding  of 
proteasomal degradation peptides to TAP for translocation into the ER, and more recently by combining 
proteasomal  degradation,  TAP  binding  and  ERAP1  trimming  to  identify  putative  epitopes  or  the 
potential impact of HLA-restricted mutations on epitope processing [50,52,88]. A prediction tool for 
cytosolic peptide stability [36], which incorporates degradation by various PBMC cytosolic peptidases, 
could be included as an additional factor influencing the amount of peptides available for presentation. 
Our even more limited knowledge of MHC-II HIV epitope production and the loose and promiscuous 
binding of peptides to MHC-II renders the prediction of MHC-II epitopes more difficult. Considering 
the importance of CD4 T helper responses to elicit sustainable CD8 T cell responses, and the intriguing 
elicitation  of MHC-II-restricted CD8 T cells  responses  after  vaccination with  an  attenuated CMV 
vector expressing SIV proteins [89], predictors for MHC-II epitope processing will be necessary; so far 
only a few predictors of peptide binding to a few MHC-II alleles are available [90–92]. The current 
datasets available on protein degradation are still insufficient to build a complete predictor recapitulating 
protein degradation and epitope presentation by MHC-I or MHC-II alleles. 
3. Antigen Processing in the Context of HIV Infection 
HIV infection induces massive changes of cellular metabolism [93] and creates unique conditions 
for antigen processing and presentation in term of targeted cell subsets and conditions for protein 
degradation. Whether HIV epitope production in HIV infection or during preventive vaccination of 
healthy donors, or therapeutic vaccination of HIV-infected persons leads to the production of similar 
epitopes and priming of protective immune responses is not known. Viruses 2014, 6  3276 
 
 
HIV infects CD4 T cells, monocytes, macrophages and dendritic cells but we do not know if they 
similarly process and present HIV epitopes during infection. Whereas all cells contain proteasomes and 
post-proteasomal peptidases, their levels of expression and hydrolytic activities in primary cell subsets 
from  a  given  individual  are  poorly  defined.  We  showed  that  primary  CD4  T  cells  present  lower 
proteasomal and aminopeptidase activities than monocytes isolated from the same donor [54]. These 
differences affected the rate of degradation of long HIV peptides into epitopes, the kinetics of epitope 
production and the amount of epitopes and extended epitopes produced. In vitro degradation of HIV p24 
by purified proteasomes from mature DC or activated CD4 T cells showed differences in the degradation 
patterns  of  p24  and  production  of  HIV  epitopes,  supporting  intrinsic  differences  in  the  hydrolytic 
activities of peptidases from different cell subsets [48]. HIV can enter cells by fusion at the plasma 
membrane or by endocytosis. The proportion of the two entry modes in various cell types is not well 
defined, not exclusive and may affect the degradation of incoming virions in infected cells. However, we 
are still lacking direct identification and comparison of HIV peptides presented by all HIV-infectable cell 
subsets and how potential differences may affect the timing and recognition of infected target cells by 
HIV-specific T cells. 
HIV infection profoundly affects the transcriptional programs of cells [93] and triggers a cytokine 
storm including production of interferon alpha, gamma and interleukins. Interferon gamma induces the 
expression of catalytic immunosubunits of proteasomes toward immunoproteasomes and increases the 
expression of several aminopeptidases (LAP, ERAP1), TAP and MHC molecules [94,95]. TNF or LPS 
can  also  induce  the  formation  of  immunoproteasomes,  but  the  impact  of  other  cytokines  or 
combination of cytokines and chemokines on the antigen processing machinery is not well defined [96]. 
Cytokines, virus or TLR ligands such as LPS or HIV RNA binding TLR7/8 trigger maturation of 
dendritic cells and macrophages. Maturation of dendritic cells reduces their antigen processing activities 
and  modifies  epitope  presentation  as  shown  previously  indirectly  through  epitope-specific  T  cell 
activation assays in various infection models [97–101].  
HIV Protease inhibitors (PI) are designed to block HIV protease catalytic sites to prevent HIV 
maturation into fully infectious particles. First generation PIs such as Saquinavir and Ritonavir present 
some cross-reactivity with proteasome catalytic sites and alter proteasome activity in vivo in mice as 
well as in human cells in vitro and LCMV-specific T cell responses in treated mice [102–106]. A recent 
study showed that HIV PIs affected not only proteasome but also aminopeptidase activities in various 
ways according to drug and concentration in human PBMC. HIV PIs modified HIV peptide degradation 
and  epitope  production,  both  in  in  vitro  degradation  assays  in  extracts  treated  with  PIs,  and  in  
HIV-infected cells endogenously processing and presenting HIV peptides to HIV-specific T cells [107]. 
Besides these external stimuli, HIV infection itself affects antigen processing. In cells isolated from 
HIV-infected donors CD4 T cells present lower activities than monocytes as seen in cells isolated from 
healthy donors. Peptidase activities in cells from HIV-infected donors were heterogeneous with a trend 
toward decrease in CD4 T cells and increase in monocytes compared to healthy donors [54]. The very 
low number of circulating HIV-infected cells and variable cellular activation levels in patients may 
contribute to the heterogeneity of antigen processing activities measured in patients’ PBMC. In vitro 
HIV  infection  alters  antigen  processing  activities  in  monocyte-derived  macrophages  [108,109]. 
Interestingly, the entry mode of HIV (infection or receptor-mediated endocytosis of naked virus or AT-2 
inactivated virus,  complement-mediated  opsonization particles) variably affects  peptidase  activities Viruses 2014, 6  3277 
 
 
and subsequently epitope presentation to T cells, at least in in vitro studies [109–111]. In vitro studies 
revealed that uptake of HIV Tat altered epitope processing activities and viral epitope presentation but 
the  impact  on  the  processing  of  HIV  is  not  known  [112].  However,  uptake  of  HIV  proteins, 
antiretrovirals  or  cytokine-induced  modifications  may  alter  antigen  processing  in  neighboring 
uninfected cells in HIV-infected persons. 
4. Exploiting Assays and Knowledge of HIV Antigen Processing and Processing for Improved 
Vaccine Design 
A commonly accepted approach to HIV vaccine design (including prophylactic vaccines protecting 
from infection or therapeutic vaccines clearing or controlling established infection) would combine a 
potent antibody response to prevent establishment of infection and sustainable T cell responses to control 
viral replication [113]. Challenges faced by vaccinologists include the genetic diversity of HIV, our 
lack  of  understanding  of  protective  immunity  (since  there  is  no  case  of  natural  clearance  of  HIV 
infection), the establishment of viral reservoirs that cannot be eliminated with antiretroviral therapy, and 
our inability to induce B cells making specific neutralizing antibodies [114]. Current areas of focus in 
vaccine development examined in in vitro studies, preclinical animal studies and clinical trials include 
designing  and  testing  various  types  of  immunogens  (proteins,  peptides,  nucleic  acids)  [115],  viral 
vectors (non-replicative or attenuated persistent) [116,117], vectorless system (nanoparticles carrying 
immunogen) [118], and adjuvants [119]. Since current clinical trials and vaccines eliciting antibodies 
are addressed elsewhere in this journal issue this review will focus on important notions to consider in 
the design of vaccines eliciting T cell immunity. 
HIV infection leads to a predictable hierarchy of T cell responses with narrow immunodominance of 
one or several T cell responses for each HLA type [64,120]. Immunodominance of T cell responses is 
defined  as  the  most  frequent  T  cell  immune  responses  (or  T  cell  responses  eliciting  the  highest 
production of interferon gamma) in a population sharing a given HLA [121,122]. Since HIV is not 
cleared by immune responses elicited during infection, a vaccine leading to the same immunodominance 
patterns as natural HIV infection will probably not be successful at preventing or clearing HIV infection. 
Two  indirect  lines  of  evidence  support  the  need  of  breaking  natural  immunodominance  during 
vaccination. First the Merck STEP clinical trial based on an adenovirus 5 vector expressing full HIV 
proteins elicited T cell immune responses in vaccinees similar to those elicited during natural HIV 
infection. However these responses failed to protect vaccinees from HIV infection or to reduce viral load 
in those who became infected [123]. Secondly an attenuated Rhesus CMV vector expressing complete 
SIV proteins (i.e., live persistent virus with attenuated capacity to replicate) led to clearance of high or 
low dose SIV infection in 50% of Rhesus macaques up to 3 years after infection. The attenuated vector 
led to broad CD4 and CD8 T cell responses with an effector phenotype that were detected both in 
blood and lymph nodes of vaccinated monkeys [124–126]. Intriguingly, most SIV-specific CD8 T cell 
responses elicited by the vaccine recognized MHC-II-restricted epitopes [89]. The mechanisms leading 
to elicitation of unconventional immune responses in all vaccinated Monkeys, their potential role in the 
clearance of infection in 50% of monkeys are still unknown. Finally the presence of dominant immune 
responses with limited antiviral capacity and the association between subdominant immune responses 
and  lower  viral  load  in  HIV-infected  persons  [127]  support  the  hypothesis  that  breaking  natural Viruses 2014, 6  3278 
 
 
immunodominance may enhance the efficacy of HIV vaccines [128]. As both attenuated CMV vectors 
and adenoviral vectors expressed complete SIV or HIV proteins, breaking immunodominance could be 
accomplished through the use of specific viral vectors. However a better understanding of the effect of 
vectors on epitope presentation and priming is required. Factors shaping immunodominance in various 
viral infections include—alone or in combination—kinetics of processing and presentation of epitopes, 
affinity  for  HLA  or  the  TCR  and  the  TCR  repertoire  [49,53,129–132].  The  identification  and  fine 
mapping of HIV-specific naï ve and memory CD4 T cell helper responses in unexposed donors showed 
that  83%  of  epitopes  share  homologies  with  microbial  organisms  (which  may  have  primed  these 
preexisting HIV-specific responses). These intriguing results suggest that the immune repertoire prior to 
HIV  infection  may  contribute  to  shaping  immunodominance  of  HIV  immune  responses  during 
infection [133]. 
Breaking  immunodominance  could  be  accomplished  through  different  approaches.  Eliminating 
known immunodominant epitopes through deletions or mutations preventing presentation [134], or 
limiting the immunogen to portions of HIV proteins assembled in a chimeric protein  [135] broke 
natural immunodominance and led to  different hierarchies of immune  responses after vaccination. 
These  immunogens  did  not  prevent  establishment  of  infection  but  offered  partial  protection  after 
challenge with  a Vaccinia virus-derived vector expressing HIV in  a mouse  model  [134]. Another 
approach to modify immunogens, successfully used to shift immunodominance in other viral infections 
in mice is to introduce mutations in region flanking epitopes so as to increase the production of some 
epitopes  and  decrease  the  production  of  others  [136–141].  The  introduction  of  cleavable  or  poorly 
cleavable motifs around HIV epitopes increased or decreased epitope processing by 10- to 100-fold and 
could  be  used  to  optimize  epitope  presentation  [47,53].  In  the  absence  of  better  understanding  of 
protective immune responses the benefit of these approaches is still limited but they provide ways to test 
and modify epitope production and presentation and to refine the design of vaccine immunogen before in 
vivo validation. 
The high variability of HIV in the infected population and across clades may require either the design 
of vaccines specific for clades or to focus the immune responses on the most conserved areas of the  
virus [115]. The emergence of escape mutations in acute HIV infection is largely predictable for many 
HLA which can be exploited in vaccine strategies. If vaccines elicit immune responses not only against 
consensus HIV sequences but also against frequent HLA-restricted mutants this will create additional 
pressure on the virus that will be forced to evolve toward variants with low replicative capacity. Mosaic 
immunogens made of a combination of distinct immunogens containing either HIV consensus sequences 
of Gag, Pol, Env (mosaic 1) or sequences carrying increasing number of frequent mutations (mosaic 2 
or 3) have been computationally engineered and inserted into adenoviral vectors [142]. These mosaic 
vectors used in prime boost combinations elicited SIV-specific CD4 and CD8 T cell and antibody 
responses,  and  significantly  reduced  the  per-exposure  risk  of  acquisition  of  SIV  [143].  Whether 
mutations introduced in mosaic 2 may alter immunogen degradation and lead to the presentation of new 
epitopes  is  not  known  but  may  broaden  immune  responses  after  vaccination.  The  opposite  and 
complementary approach to the mosaic is the design of immunogens limited to the most conserved areas 
of several HIV proteins and when needed the most frequent variant of the sequence so as to cover >98% 
of HIV sequences [135,144,145]. Conserved sequences constitute vulnerable areas of the virus that can 
be identified in a linear fashion by sequence comparison in cohorts of HIV-infected persons [146], or as Viruses 2014, 6  3279 
 
 
sectors of HIV proteins that coevolve at multiple sites under a given HLA pressure [73,147]. Peptides 
corresponding to conserved areas can be assembled in a chimeric protein by addition of linkers that do 
not create new epitopes based on the presence of potential anchors but introduce efficient cleavage sites 
for liberation of HIV fragments. These immunogens used in DNA prime/boost vaccination elicited 
CD4, CD8 T cell and antibodies responses in mice and Macaques and will eventually be tested in 
clinical trials [148,149]. Alternatively, peptides from conserved areas of HIV proteins may be used in 
peptide-based vaccines where peptides and adjuvants are electroporated [150] or carried to lymph nodes 
by nanoparticles [151]. In addition to conserved and variable areas of HIV proteins, cryptic epitopes 
generated from alternate reading frames could potentially be included in HIV immunogens, provided that 
immune responses against these epitopes are shown to contribute to reducing viral load. 
The choice of vectors and adjuvants and the specific subset of dendritic cells endocytosing the 
vaccine and could also alter conditions in which the peptides are processed [119,152–154]. Adjuvants 
such as CpG, TLR ligands will trigger changes in hydrolytic activities of endolysosomal peptidases, 
epitope production and presentation, and possibly affect priming of immune responses  [155–157]. 
Virus-derived vectors such as adenovirus or CMV could elicit or recall T cell immunity against these 
viruses  and  may  alter  the  overall  hierarchy  of  immune  responses  against  the  immunogen  after 
vaccination. Replication-competent viruses used as persistent vectors might interact with the antigen 
processing machinery and possibly affect production of epitopes. The elicitation of MHC-II-restricted 
CD8 T cell responses by attenuated CMV vectors expressing SIV antigens in vaccinated monkeys sheds 
light on our limited understanding of conditions established by vectors for priming of immune responses 
but open new avenues to manipulate immunodominance and immunity during vaccination [158]. 
Therapeutic vaccines aiming at clearing or substantially reducing HIV infection is urgently needed 
to replace lifelong treatment of the HIV-infected population. One approach consists in combining 
reactivation of HIV provirus with drugs such as HDAC inhibitors with vaccines boosting HIV immune 
responses in HIV-infected persons receiving ART [159,160]. Latent infection of CD4 T cells, provirus 
reactivation  and  ART  might  create  unique  conditions  for  the  processing  and  presentation  of  HIV 
epitopes. Defining epitopes presented in the context of latency (if any) and of reactivation will be 
necessary to better define epitopes and corresponding immune responses that should be boosted by 
therapeutic vaccines. 
Further studies are needed to identify protective immune responses for prophylactic and therapeutic 
vaccines, specifically with regards to epitope specificity covering various HLA, ratio or phenotypes of 
CD4 and CD8 T cell responses, and how to specifically induce them during vaccination. Guiding 
principles such as encompassing viral diversity or focusing on conserved areas, adequate matching 
epitope presentation between infected cells and DC receiving vaccines are defined, and multiple tools 
to study epitope production and immune responses are available. Regardless of the vector or adjuvants 
used for vaccination, the HIV immunogen will have to be processed in professional antigen presenting 
cells for the priming of immune responses. It is necessary to ensure that—in the context established by 
the specific vaccination strategies discussed above—this HIV immunogen will be properly degraded 
into MHC-I and MHC-II epitopes corresponding to sustainable protective immune responses able to 
recognize infected cells. Assays to follow protein degradation into epitopes and motifs to optimize 
epitope provide a way to test epitope production from vaccine immunogens before larger studies in Viruses 2014, 6  3280 
 
 
animal models and clinical trials, and guidelines to the design of immunogens leading to optimized 
epitope presentation. 
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